B+
Bull case
20%
Probability
Target price
$4.50
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
CABA
Cabaletta BioDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
45%
Probability
Target price
$2.50
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
B-
Bear case
35%
Probability
Target price
$1.25
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-08
Recent news sentiment (30D)
+0.1
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+52.1
Score
AI commentary
Primary company news remains clinically constructive, but the post-earnings evidence set is incomplete and the peer frame is too weak to support standard conviction. The packet's August 6 adjusted close was $2.76, without a pre/post earnings comparison, so the market reaction cannot be attributed. Social, options, short-interest, employee, and post-print analyst data were unavailable; missing reaction and peer data are not treated as positive evidence.
RankAlpha Sentiment Codex - 2026-08-08
Open post-earnings memoEvidence flagged
small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report
Impact
tentative
Confidence
-
AI events
2026-12-31eventSSc registrational program initiation anticipated in 4Q26High impact
The company reported encouraging Phase 1/2 systemic-sclerosis data and identified SSc as its second pivotal indication, with a single-arm study of approximately 25 patients anticipated to start in 4Q26 [#PR-2026-06-03].
2026-12-31eventAdditional preconditioning-free rese-cel dose-ranging dataHigh impact
The latest stored earnings update described planned second-half 2026 reporting of longer-term PC-free data and higher-dose cohorts across autoimmune indications; timing and durability remain uncertain [#SEC-8K-2026-05-14] [#PR-EARNINGS-2026-05-14].
2027-06-30catalystRegistrational myositis topline data and BLA pathHigh impact
Management anticipates topline data from the registrational DM/ASyS cohort in mid-2027 and has outlined a potential 2H27 BLA submission including juvenile and adult dermatomyositis [#PR-2026-06-03].
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-08 • Updated nightlySource: Internal modelMethodology